ABG
VRNA

Ally Bridge Group’s Verona Pharma VRNA Stock Holding History

Ally Bridge Group’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-160,701
Closed -$15.2M – 37
2025
Q2 		$15.2M Buy
160,701
+21,634
+16% +$1.6M 12.65% 1
2025
Q1 		$8.83M Buy
+139,067
New +$8.32M 7.96% 2
2024
Q2 		– Sell
-736,738
Closed -$11.9M – 31
2024
Q1 		$11.9M Buy
+736,738
New +$12.7M 6.59% 5
2023
Q3 		– Sell
-487,631
Closed -$10.3M – 23
2023
Q2 		$10.3M Hold
487,631
– – 12.49% 2
2023
Q1 		$9.79M Buy
+487,631
New +$10.5M 12.83% 1

Other funds holding VRNA

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Ally Bridge Group's VRNA Position: Q3 2025 in Review

Ally Bridge Group sold out of Verona Pharma (VRNA) in Q3 2025, closing a stake of 160,701 shares — an estimated $15.2M sold.

Ally Bridge Group first reported a position in VRNA in Q1 2023 and held it in 5 quarters. The position peaked at $15.2M in Q2 2025. 243 funds tracked by Wall St. Rank hold VRNA as of Q3 2025.

  • Ally Bridge Group reported no remaining Verona Pharma position as of Q3 2025 after selling out during the quarter.
  • Ally Bridge Group sold 160,701 Verona Pharma shares in Q3 2025, an estimated $15.2M.
  • Ally Bridge Group first reported a position in Verona Pharma in Q1 2023 and held it in 5 quarters.
  • Ally Bridge Group's Verona Pharma position peaked at $15.2M in Q2 2025.
  • 243 funds tracked by Wall St. Rank held Verona Pharma as of Q3 2025.

Based on Ally Bridge Group's 13F filing for Q3 2025, filed 14 Nov 2025.